US EditionPublished • loading... • Updated
JPM26: J&J leans on immunology launches to fuel annual growth - Pharmaceutical Technology
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
JPM26: HIV pipeline dosing optionality gives Gilead advantage
Speaking at the J.P. Morgan Healthcare Conference 2026, CEO Daniel O’Day said that the company has seven pipeline drugs for HIV.The post JPM26: HIV pipeline dosing optionality gives Gilead advantage appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
